-
Mashup Score: 4Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years - 11 month(s) ago
NMV-r use for Covid-19 in vaccinated adults aged 18-50, with serious comorbidities, was associated with improved clinical outcomes. However, patients without si
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Former Pfizer statistician is charged with insider trading over Paxlovid clinical trial results - 11 month(s) ago
A former Pfizer statistician was charged by U.S. authorities with insider trading for acting on advance information about trial results for the Paxlovid Covid-19 treatment.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0New antiviral, Paxlovid, added to PANORAMIC study - 12 month(s) ago
From today, the antiviral treatment Paxlovid has been included in the national PANORAMIC study, the UK’s fastest ever recruiting clinical trial of its kind, run by the Nuffield Department of Primary Care Health Sciences and supported by the National Institute for Health and Care research (NIHR).
Source: www.panoramictrial.orgCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 0Staying Current With Drug Interactions - 1 year(s) ago
A clinician provides insights on this significant topic as well as resources in finding information on them.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
Background: Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection (PASC) is unknown. The objective of this stu
Source: papers.ssrn.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Simulations suggest deaths from COVID-19 could be cut in half if 80% of eligible patients took the antiviral therapy.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 17
An FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Source: ABC NewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 11Nirmatrelvir and the Risk of Post–COVID-19 Condition - 1 year(s) ago
This cohort study examines the association of treatment with nirmatrelvir in the acute phase of COVID-19 and risk of post–COVID-19 condition.
Source: jamanetwork.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 17Nirmatrelvir and the Risk of Post–COVID-19 Condition - 1 year(s) ago
This cohort study examines the association of treatment with nirmatrelvir in the acute phase of COVID-19 and risk of post–COVID-19 condition.
Source: jamanetwork.comCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 1
AMA Vice President of Science, Medicine and Public Health Andrea Garcia, JD, MPH, covers the latest news physicians need to know, including: new updates from…
Source: YouTubeCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
Our Study @CIDJournal led by @jeremyfaust @PaulSaxMD #Paxlovid for Covid-19 in #Young (18-50) Vaccinated Patients with comorbidities (ie #CVD #Cancer #cardioonc) requiring frequent healthcare improves outcomes⬇️#death #hospitalization #Emergency visits https://t.co/tkdeV0XFNv